UCB :: The next generation biopharma leader

Welcome to UCB

UCB, Inc., with headquarters in Atlanta, Ga., is a wholly owned subsidiary and U.S. affiliate of
UCB S.A.

UCB, Brussels, Belgium, is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders.

Latest news

New data for Vimpat® (lacosamide) C-V showed sustained efficacy for up to 5 years and improved seizure control when added to a broad range of antiepileptic drugs29-June-2010 | pdf file, 101 kb
Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Leg Syndrome18-June-2010 | pdf file, 64 kb
Neupro® (rotigotine transdermal system) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson's disease17-June-2010 | pdf file, 61 kb
New data presented from EMBLEM™ study for pipeline drug epratuzumab for patients suffering from moderate to severe systemiclupus erythematosus16-June-2010 | pdf file, 55 kb
Long-term Cimzia® (certolizumab pegol) data demonstrated rapid sustained improvements in clinical outcomes and quality of life in moderate to severe rheumatoid arthritis (RA) patients16-June-2010 | pdf file, 101 kb

More newsLorem

Patients

Already the leader in epilepsy, UCB is committed to providing novel solutions for people with severe conditions such as Parkinson's disease, rheumatoid arthritis, restless legs syndrome...

lorem

Journalists

UCB is in the news. For more information, click here.

lorem

Job Seekers

Join us and make a world of difference as we build the next generation biopharma, supported by a dynamic team in the U.S. and abroad.

lorem

About UCB in the U.S.

For more information about UCB in the U.S., click here.

lorem